As 90% of HNSCC overexpress the gene for the epidermal growth factor receptor (EGFR), a targeted antibody therapy to EGFR, cetuximab, has been examined in combination with radiation therapy and has been observed to decrease locoregional tumor burden and reduce mortality1,13–15. Here, EGFR is linked to neoplasm.